11/15
Cancer Research
Genetic switch turns tumor suppressor into oncogene in colorectal cancer
Genetic switch turns tumor suppressor into oncogene in colorectal cancer
Researchers from the School of Veterinary Medicine have shown that an enzyme that suppresses early-stage colorectal cancer switches to become an oncogene as the cancer progresses.
An immunotherapy strategy against all blood cancers
An immunotherapy strategy against all blood cancers
Researchers at Penn Medicine have demonstrated a new potential treatment using CAR T cell therapy using a CRISPR base-editing to develop a method called “epitope editing.”
Carl June on the boundless potential of CAR T cell therapy
Carl June on the boundless potential of CAR T cell therapy
In a Q & A, June, the Richard W. Vague Professor in Immunotherapy, and Daniel Baker, a fourth-year doctoral student in Penn’s Cell and Molecular Biology department, discuss how the treatment can extend to treating diseases beyond cancer.
QR code for cancer cells
Researchers from Penn Engineering have created a new synthetic biology approach to uncover why some cells become resistant to anti-cancer therapies.
Antibody treatment prevents graft versus host disease in advanced preclinical tests
Antibody treatment prevents graft versus host disease in advanced preclinical tests
Penn Medicine, Dana-Farber Cancer Institute, and Boston Children’s Hospital research finds single antibody treatment blocked donor T-cell attack and increased survival rates in preclinical models.
RNA nanoparticle therapy stops the spread of incurable bone marrow cancer
RNA nanoparticle therapy stops the spread of incurable bone marrow cancer
By creating a roadblock in cancer’s commute through the body, researchers removed a longstanding barrier in the treatment of multiple myeloma.
Data suggests stopping immunotherapy after two years is reasonable in patients with advanced lung cancer
Data suggests stopping immunotherapy after two years is reasonable in patients with advanced lung cancer
A new Penn Medicine study finds indefinite immunotherapy is not associated with improved survival in large, retrospective cohort.
Why new cancer treatment discoveries are proliferating
Why new cancer treatment discoveries are proliferating
The approval of CAR T cell therapy ushered in a new era for cancer treatment.
The path from innovation to implementation
The path from innovation to implementation
Penn’s infrastructure in both supporting clinical research and forging commercial partnerships smooths the way from idea to approval.
Three things to know about BRCA mutations in men
Three things to know about BRCA mutations in men
Kara Maxwell, director of the Men & BRCA Program at the Basser Center, is bridging the knowledge gap about how BRCA mutations affect men.
In the News
Forbes
Carl June: 2024 will be seen as a breakthrough year for brain cancer
Carl June of the Perelman School of Medicine shares five insights on using CAR T cell therapy to combat cancer, featuring remarks from Bruce Levine.
FULL STORY →
Philadelphia Inquirer
Penn plans to build a proton center for cancer treatment at Presbyterian Medical Center
Penn Medicine will build its fourth proton beam center for cancer treatment at Penn Presbyterian Medical Center in University City.
FULL STORY →
PhillyVoice
Double mastectomies do not improve breast cancer survival likelihood for most women, study finds
Angela DeMichele of the Perelman School of Medicine says that chemotherapy and hormonal therapies are important for combating breast cancer because they’re designed to kill spreading cells.
FULL STORY →
The New York Times
Breast cancer survival not boosted by double mastectomy, study says
Angela DeMichele of the Perelman School of Medicine comments on a study which found that breast cancer survival is not boosted by a double mastectomy.
FULL STORY →
Today
How did Shannen Doherty die? What to know about ‘90210’ star’s cause of death
According to Penn Medicine, there is no known cure for metastatic breast cancer.
FULL STORY →
Stat
New immunotherapy combination could ‘change the landscape’ of cancer treatment
A study by Andy Minn and postdoc Divij Mathew of the Perelman School of Medicine and colleagues found that a combination checkpoint inhibitor therapy benefited patients with lung cancer.
FULL STORY →